Mutations in the mitochondrial genome confer resistance of cancer cells to anticancer drugs Mizutani S et al. - The mutant mtDNA showed better survival, indicating that mutant cybrids were more resistant to the anticancer drugs. Thus, the authors propose that mutations in the mitochondrial genome are potential targets for prognosis in the administration of anticancer drugs to cancer patients. [more...]
